Why strength training matters on a GLP-1
GLP-1 and GLP-1/GIP medications (semaglutide, liraglutide, tirzepatide) produce substantial weight loss — often 15-24% of body weight in clinical trials. But not all of that weight is fat. Research shows lean soft tissue (muscle, and some bone) can make up roughly 25-40% of total weight lost, which is a meaningfully larger share than what's typically seen with diet-only weight loss. That's a loss of muscle comparable to a decade or more of natural age-related decline, compressed into months.
Losing that much muscle matters beyond the number on the scale. Muscle drives your resting metabolism, your strength and mobility, and your ability to keep weight off long-term. Preserving it is one of the few levers you fully control during treatment — and strength training is the most effective one available.
Is the medication itself causing muscle loss?
A common question is whether GLP-1 drugs directly break down muscle tissue, or whether the muscle loss is simply a side effect of losing weight quickly by any method. Based on the current research, the honest answer is: mostly indirect, with one open question.
- Muscle loss during rapid weight loss isn't unique to GLP-1 drugs — it happens with diet-only weight loss and bariatric surgery too. What stands out with GLP-1/GIP medications is the proportion: lean tissue has been reported to make up ~25-40% of total weight lost in trials, higher than what's typically seen with slower, diet-driven weight loss (DOI (external link)). This points to the speed and magnitude of weight loss — which these drugs accelerate — as the main driver, rather than a unique pharmacological effect on muscle tissue itself.
- No study to date has isolated GLP-1 receptor activity as a direct cause of muscle breakdown, separate from the caloric deficit and rapid fat loss the drugs produce. Reviews frame lean mass loss as a downstream consequence of the weight-loss process, not a direct drug effect (DOI (external link)).
- There is one emerging exception worth flagging: a 2026 review found that in older adults on long-term semaglutide, grip strength declined and sarcopenia risk increased even in ways that didn't track cleanly with lean mass changes seen in shorter trials — raising the possibility of a strength-specific effect beyond simple loss of muscle tissue. This evidence is preliminary and mostly observational, and more controlled, longer-term research is needed (DOI (external link)).
In short: for most people, muscle loss on a GLP-1 is best understood as a consequence of losing weight quickly — not evidence that the drug is attacking muscle directly — but it's a real and significant effect regardless of mechanism, which is exactly why proactive strength training and adequate protein matter.
What the research shows
According to PubMed, several recent reviews and studies point to the same conclusion: resistance exercise is the key intervention for protecting muscle during GLP-1 treatment.
- A 2024 review in Diabetes Care found that supervised resistance training lasting more than 10 weeks produced meaningful gains in lean mass (~3 kg) and strength (~25%) even while patients were losing significant weight on incretin therapy — and proposed resistance training be recommended as a standard adjunct to these medications (DOI (external link)).
- A 2025 case series in SAGE Open Medical Case Reports followed three patients who combined semaglutide or tirzepatide with resistance training 3-5 days/week and higher protein intake. Two of the three actually gained lean tissue while losing 27-62% of their fat mass (DOI (external link)).
- A 2025 narrative review in Nutrients concluded that structured resistance training, combined with adequate protein and other nutrients, is critical to preserving muscle and bone during incretin-based treatment (DOI (external link)).
- A 2025 clinical guidance article from the International Symposium on Diabetes and Nutrition recommends protein intake above 1.2 g/kg/day, spread evenly across meals, combined with both aerobic activity and structured resistance training, as the core strategy for preserving lean mass (DOI (external link)).
One caution worth noting: a 2026 review in the British Journal of Pharmacology found that while short-term studies show muscle strength holding up despite tissue loss, longer-term data in older adults on semaglutide showed declines in grip strength and accelerated sarcopenia risk — a reminder that muscle mass and muscle strength aren't the same thing, and that ongoing strength training (not just early efforts) matters over the full course of treatment (DOI (external link)).
When to start
The research supports starting resistance training as early as possible — ideally alongside your first doses, rather than waiting until you've lost weight or side effects have settled. Muscle loss tends to track with the pace of weight loss, and that pace is often fastest in the early months of treatment. Waiting means losing ground you'll have to work harder to regain.
Practical starting points:
- Start light and build. If you're new to strength training or dealing with GI side effects (nausea, low appetite) in the early weeks, start with 2 sessions a week of basic, full-body movements (bodyweight squats, rows, presses) before adding load.
- Prioritize protein alongside training. Multiple reviews cite protein intakes above ~1.2 g/kg/day, distributed across meals, as necessary to get the full muscle-preserving benefit of resistance training — training alone without adequate protein is less effective.
- Check in with your prescriber if you have cardiovascular conditions, joint issues, or significant GI side effects before starting a new exercise routine.
How it compares to other exercise
Not all exercise protects muscle equally during GLP-1 treatment:
| Exercise type | Effect on lean mass | Best used for |
|---|---|---|
| Resistance/strength training | Directly stimulates muscle protein synthesis; the strongest evidence for preserving or even growing lean mass during weight loss | Preserving muscle and strength — the primary tool |
| Aerobic exercise (walking, cycling, running) | Supports cardiovascular health and adds to total weight/fat loss, but does not by itself protect lean mass | Cardiometabolic health, added fat loss, weight-loss maintenance |
| Combined resistance + aerobic | Clinical guidance consistently recommends both together rather than either alone | Comprehensive body composition and health outcomes |
| No structured exercise | Highest reported lean mass loss as a share of total weight lost | Not recommended during GLP-1 treatment if avoidable |
A 2024 review specifically noted that combining aerobic exercise with liraglutide improved weight-loss maintenance after a low-calorie diet compared with either alone — meaning aerobic work still has a role, particularly for keeping weight off, even though resistance training is the more direct tool for preserving muscle (DOI (external link)). Clinical guidance overwhelmingly frames this as "both, not either" — aerobic activity for cardiometabolic and weight-maintenance benefits, resistance training as the non-negotiable piece for protecting the muscle you have.
The bottom line
If you're on a GLP-1 medication and want to protect your strength, mobility, and metabolism through weight loss, strength training isn't optional — start early, aim for 2-3+ sessions a week of resistance work, pair it with adequate protein, and don't rely on cardio alone to do the job. Whether the muscle loss comes from the drug directly or simply from losing weight quickly, the response is the same either way.